Biotechnology Centre of Oslo and Centre for Molecular Medicine, Nordic EMBL Partnership, University of Oslo, PO Box 1125, Blindern, N-0317 Oslo, Norway
(Correspondence should be addressed to K Taskén; Email: kjetil.tasken{at}biotek.uio.no)
cAMP signal pathways. Ligand binding to various G protein-coupled receptors (GPCRs) activates adenylyl cyclase in their proximity
and generates pools of cAMP. The local concentration and distribution of the cAMP gradient are limited by phosphodiesterases
(PDEs). Particular GPCRs are confined to specific domains of the cell membrane in association with intracellular organelles
or cytoskeletal constituents. The subcellular structures may harbor specific isozymes of PKA that, through anchoring via AKAPs,
are localized in the vicinity of the receptor and the cyclase. PDEs are also anchored and serve to limit the extension and
duration of cAMP gradients. These mechanisms serve to localize and limit the assembly and triggering of specific pathways
to a defined area of the cell close to the substrate. cAMP (red filled circles) has effects on a range of effector molecules
encompassing 1) PKA, 2) PDEs, 3) guanine nucleotide exchange factors (GEFs) known as exchange proteins activated by cAMP (Epacs),
and 4) cyclic nucleotide-gated ion channels.
Illustration of AKAP properties. (A) AKAPs share three common properties: 1) AKAPs bind to the regulatory subunit of PKA through
a conserved anchoring domain; 2) a unique subcellular targeting domain directs AKAP-signaling complexes to discrete locations
inside a cell; and 3) additional binding sites for other signaling proteins such as kinases, phosphatases, or potential substrates.
(B) Ribbon diagram of the NMR structure of RIIα (1–43) dimer (yellow, blue, and red) and the AKAP amphipathic helix peptide
(green; Newlon et al. 2001) depicted using Accelrys Discovery Studio 2.5.1 based on the coordinates from PDB (http://www.rcsb.org/pdb/explore/explore.do?structureId=2DRN).
Schematic illustration of the effect of specific anchoring disruptor peptides. (A) Model of type I PKA and type II PKA signal
complexes organized by specific AKAPs and mediating biological effects 1 and 2 respectively. (B and C) Models for effect of
RIAD or SuperAKAP-IS on biological effects 1 and 2. (D and E) Effect of RIAD and SuperAKAP-IS together or Ht31 on biological effects 1 and 2. cAMP, red-filled circles; phosphate, blue-filled circles.
Signal complex consisting of mAKAP, PKA, PDE4D3, Epac, and a MEKK/MEK5/ERK5 module. mAKAP anchors PKA and PDE4D3, whereas
PDE4D3 scaffolds an Epac–Rap1 pathway that coordinates a MEKK/MEK5/ERK5 module. cAMP, red-filled circle; phosphate, blue-filled
circle.
PKA–AKAP18δ–PLB–SERCA2 complex. (A) Resting situation, no adrenergic drive, low heart rate, SERCA2 inhibited by PLB with low
ATP and energy consumption. (B) Adrenergic stimulation paces the heart and increased heart rate. SERCA2 released from PLB
inhibition by PKA phosphorylation leading to fast Ca2+ reabsorption and high ATP and energy consumption.